Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
6 Articles
6 Articles
Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder
Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants
NEW YORK, July 28, 2026, 09:07 EDT The stock climbed roughly 10% in premarket trading after closing at $2.96 on Monday. (Reuters) Pemvidutide led to a decrease of 1.45 heavy-drinking days per week compared to placebo. (SEC) The increase lifted 75 million warrants past their $3 exercise threshold. (SEC) Altimmune stock gained roughly 10% in…
Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a weekly shot of pemvidutide or placebo ...
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
